Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biocine

Executive Summary

Experimental post-infection hepatitis C vaccine from the Chiron/Ciba-Geigy vaccine joint venture is targeted to move into clinical trials in the "second half" of 1994 based on the vaccine's demonstrated protection against the liver disease in an 11 chimpanzee study, Chiron Chairman Ed Penhoet advises Alex. Brown health care conference May 10. Five of the seven chimps immunized with the vaccine 30-40 weeks prior to challenges with infected serum did not contract infections, while all four of the control chimps challenged did get infections. The chimps have been followed a minimum of six months. The immunized chimps that became infected had weak antibody responses. In one of the two infected chimps, "there was a significant delay in the onset of infection as compared with the four non-immunized control animals," the company notes. The vaccines use two HCV envelope region antigens combined with the adjuvant MF59 or MF75 combined with muramyle tripeptide.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS022603

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel